The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Lawton Vincent Michael | Director | Grant(A) | 502K | — | $0 |
| Sep 2, 2026 | Lawton Vincent Michael | Director | Disposed to issuer(D) | 502K | — | $0 |
| Sep 2, 2026 | Lawton Vincent Michael | Director | Grant(A) | 2.5M | — | $0 |
| Sep 2, 2026 | Lawton Vincent Michael | Director | Disposed to issuer(D) | 2.5M | — | $0 |
| Sep 2, 2026 | Hill Raymond George | Director | Grant(A) | 273K | — | $0 |
| Sep 2, 2026 | Hill Raymond George | Director | Disposed to issuer(D) | 273K | — | $0 |
| Sep 2, 2026 | Hill Raymond George | Director | Grant(A) | 1.4M | — | $0 |
| Sep 2, 2026 | Hill Raymond George | Director | Disposed to issuer(D) | 1.4M | — | $0 |
| Sep 2, 2026 | Dyer Timothy Mark | CHIEF EXECUTIVE OFFICER, Director | Grant(A) | 3.4M | — | $0 |
| Sep 2, 2026 | Dyer Timothy Mark | CHIEF EXECUTIVE OFFICER, Director | Disposed to issuer(D) | 3.4M | — | $0 |
| Sep 2, 2026 | Dyer Timothy Mark | CHIEF EXECUTIVE OFFICER, Director | Grant(A) | 16.4M | — | $0 |
| Sep 2, 2026 | Dyer Timothy Mark | CHIEF EXECUTIVE OFFICER, Director | Disposed to issuer(D) | 16.4M | — | $0 |
| Sep 2, 2026 | Kalinichev Mikhail | HEAD OF TRANSLATIONAL SCIENCE | Grant(A) | 200K | — | $0 |
| Sep 2, 2026 | Kalinichev Mikhail | HEAD OF TRANSLATIONAL SCIENCE | Disposed to issuer(D) | 200K | — | $0 |
| Sep 2, 2026 | Kalinichev Mikhail | HEAD OF TRANSLATIONAL SCIENCE | Grant(A) | 307K | — | $0 |
| Sep 2, 2026 | Kalinichev Mikhail | HEAD OF TRANSLATIONAL SCIENCE | Disposed to issuer(D) | 307K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 100K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 100K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 209K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 209K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 91K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 91K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 66K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 66K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 30K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 30K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 10K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 10K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 60K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 60K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Grant(A) | 38K | — | $0 |
| Sep 2, 2026 | Teyssedou Lenaic Nathanael | PRINCIPAL ACCOUNTING OFFICER | Disposed to issuer(D) | 38K | — | $0 |
| Sep 2, 2026 | Manke Isaac | Director | Grant(A) | 50K | — | $0 |
| Sep 2, 2026 | Manke Isaac | Director | Disposed to issuer(D) | 50K | — | $0 |
| Sep 2, 2026 | Manke Isaac | Director | Grant(A) | 220K | — | $0 |
| Sep 2, 2026 | Manke Isaac | Director | Disposed to issuer(D) | 220K | — | $0 |
| Sep 2, 2026 | Mills Roger | CHIEF MEDICAL OFFICER, Director | Grant(A) | 50K | — | $0 |
| Sep 2, 2026 | Mills Roger | CHIEF MEDICAL OFFICER, Director | Disposed to issuer(D) | 50K | — | $0 |
| Sep 2, 2026 | Mills Roger | CHIEF MEDICAL OFFICER, Director | Grant(A) | 393K | — | $0 |
| Sep 2, 2026 | Mills Roger | CHIEF MEDICAL OFFICER, Director | Disposed to issuer(D) | 393K | — | $0 |
| Sep 2, 2026 | Nunn Jason Raleigh | Director | Grant(A) | 50K | — | $0 |
| Sep 2, 2026 | Nunn Jason Raleigh | Director | Disposed to issuer(D) | 50K | — | $0 |
| Sep 2, 2026 | Nunn Jason Raleigh | Director | Grant(A) | 220K | — | $0 |
| Sep 2, 2026 | Nunn Jason Raleigh | Director | Disposed to issuer(D) | 220K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Addex Therapeutics Ltd., SEC CIK 0001574232. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ADXN and shows every filing by that issuer.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ADXN